Falcon Point Capital LLC boosted its holdings in shares of Cardiovascular Systems Inc (NASDAQ:CSII) by 11.5% in the second quarter, according to its most recent filing with the SEC. The firm owned 160,405 shares of the medical device company’s stock after acquiring an additional 16,577 shares during the period. Cardiovascular Systems accounts for 3.7% of Falcon Point Capital LLC’s portfolio, making the stock its largest position. Falcon Point Capital LLC owned 0.46% of Cardiovascular Systems worth $6,886,000 as of its most recent SEC filing.
A number of other institutional investors and hedge funds have also added to or reduced their stakes in CSII. Pearl River Capital LLC bought a new stake in shares of Cardiovascular Systems in the 1st quarter worth approximately $98,000. BerganKDV Wealth Management LLC bought a new stake in shares of Cardiovascular Systems in the 1st quarter worth approximately $155,000. Legal & General Group Plc lifted its holdings in shares of Cardiovascular Systems by 21.7% in the 4th quarter. Legal & General Group Plc now owns 6,065 shares of the medical device company’s stock worth $173,000 after acquiring an additional 1,082 shares during the last quarter. LS Investment Advisors LLC bought a new stake in Cardiovascular Systems during the 1st quarter valued at $201,000. Finally, Country Club Trust Company n.a. bought a new stake in Cardiovascular Systems during the 1st quarter valued at $232,000. 92.30% of the stock is owned by hedge funds and other institutional investors.
Shares of Cardiovascular Systems stock opened at $47.01 on Friday. The firm’s 50-day moving average is $44.69 and its 200 day moving average is $39.50. The stock has a market cap of $1.66 billion, a price-to-earnings ratio of -4,701.00 and a beta of 1.77. Cardiovascular Systems Inc has a 1 year low of $24.84 and a 1 year high of $49.37. The company has a debt-to-equity ratio of 0.14, a current ratio of 4.25 and a quick ratio of 3.83.
Cardiovascular Systems (NASDAQ:CSII) last released its earnings results on Tuesday, August 6th. The medical device company reported $0.04 earnings per share (EPS) for the quarter, hitting the Thomson Reuters’ consensus estimate of $0.04. Cardiovascular Systems had a negative net margin of 0.10% and a negative return on equity of 0.18%. The company had revenue of $68.23 million during the quarter, compared to analyst estimates of $66.04 million. On average, equities analysts expect that Cardiovascular Systems Inc will post 0.02 EPS for the current fiscal year.
A number of equities research analysts recently commented on the stock. Needham & Company LLC reiterated a “hold” rating on shares of Cardiovascular Systems in a report on Wednesday, August 7th. Zacks Investment Research lowered shares of Cardiovascular Systems from a “hold” rating to a “strong sell” rating and set a $47.00 price target for the company. in a report on Thursday, August 8th. BidaskClub raised shares of Cardiovascular Systems from a “sell” rating to a “hold” rating in a research report on Friday, August 9th. Stifel Nicolaus downgraded shares of Cardiovascular Systems from a “buy” rating to a “hold” rating and boosted their price objective for the company from $41.00 to $45.00 in a research report on Tuesday, July 16th. They noted that the move was a valuation call. Finally, Lake Street Capital upped their target price on shares of Cardiovascular Systems from $50.00 to $60.00 and gave the stock a “buy” rating in a research report on Wednesday, August 7th. Two analysts have rated the stock with a sell rating, three have given a hold rating, one has issued a buy rating and one has given a strong buy rating to the stock. The company presently has an average rating of “Hold” and a consensus price target of $48.50.
Cardiovascular Systems Profile
Cardiovascular Systems, Inc, a medical device company, develops, manufactures, and commercializes various devices to treat vascular and coronary diseases in the United States. The company offers peripheral arterial disease products, including Diamondback 360 Peripheral, Predator 360, Stealth 360 Peripheral Orbital Atherectomy System (OAS), Diamondback 360 60cm Peripheral OAS, Diamondback 360 Low Profile Peripheral, Diamondback 360 1.50 Peripheral, Diamondback 360 2.00 Peripheral, Diamondback 360 200cm Peripheral, and Diamondback 360 180cm Peripheral, which are catheter-based platforms for treating a range of plaque types in leg arteries above and below the knee, including calcified plaque, as well as address various limitations associated with surgical, catheter, and pharmacological treatment alternatives.
Receive News & Ratings for Cardiovascular Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardiovascular Systems and related companies with MarketBeat.com's FREE daily email newsletter.